A phase III trial to investigate the efficacy and safety of CPC-201 in patients with Alzheimer's disease

Trial Profile

A phase III trial to investigate the efficacy and safety of CPC-201 in patients with Alzheimer's disease

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Donepezil/solifenacin (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Nov 2016 According to an Allergan media release, the company intends to advance this study in 2017.
    • 06 Jun 2016 According to a Chase Pharmaceuticals media release, the company is about to complete the final trial protocol.
    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top